ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,802Medicare Part D Prescriptions Filled, Including Refills

Rank: 304 out of 890

$348K Total Retail Price of All Prescriptions

Rank: 376 out of 890

415 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 415 patients filled at least one prescription for a schedule two drug, compared to an average of 2%.

Schedule Three
Controlled Substances

25% of this provider’s 415 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

4% of this provider’s 6,676 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
HYDROCODONE-ACETAMINOPHEN 377 269 S3 1 3
SIMVASTATIN 343 315 2 5
ATENOLOL 250 225 3 23
LISINOPRIL 234 206 4 4
HYDROCHLOROTHIAZIDE 232 202 5 9
FUROSEMIDE 224 213 6 7
OMEPRAZOLE 223 184 7 8
POTASSIUM CHLORIDE 216 199 8 11
METFORMIN HCL 186 168 9 6
MELOXICAM 172 150 10 18
LEVOTHYROXINE SODIUM 165 150 11 2
GABAPENTIN 118 86 12 12
AMLODIPINE BESYLATE 115 114 13 1
CITALOPRAM HBR 114 109 14 20
LISINOPRIL-HYDROCHLOROTHIAZIDE 107 92 15 21
DOXYCYCLINE HYCLATE 106 92 16 89
WARFARIN SODIUM 94 94 17 24
METOPROLOL TARTRATE 89 76 18 15
ATORVASTATIN CALCIUM 79 77 19 13
LACTULOSE 73 57 20 112
TAMSULOSIN HCL 70 58 21 32
JANUVIA 67 67 22 59
NEXIUM 67 65 22 14
TRAMADOL HCL 63 50 24 16
ALLOPURINOL 63 51 24 31
MECLIZINE HCL 58 58 26 97
CLONIDINE HCL 58 55 26 35
PANTOPRAZOLE SODIUM 57 37 28 34
CARISOPRODOL 55 39 R 29 69
NIFEDIPINE ER 54 53 30 75
LANTUS 54 49 30 50
MEGESTROL ACETATE 53 52 R 32 92
POLYETHYLENE GLYCOL 3350 53 51 32 67
DONEPEZIL HCL 52 52 34 30
PREMARIN 52 47 R 34 105
DIVALPROEX SODIUM 50 49 36 126
CLOPIDOGREL 50 47 36 28
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 9, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.